Back to top

crispr: Archive

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

VRTXNegative Net Change PBYIPositive Net Change NTLAPositive Net Change CRSPPositive Net Change